BRISTOL-MYERS SQUIBB COMPANY Equity Security Fv Ni Contractual Sale Restriction
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Equity Security Fv Ni Contractual Sale Restriction of $123.00 million as of 2024-03-31, per its 10-Q filed 2024-04-25.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecurityFvNiContractualSaleRestriction · last filed 2024-04-25
- 2024-03-31: Equity Security Fv Ni Contractual Sale Restriction $123.00M.
- 2023-12-31: Equity Security Fv Ni Contractual Sale Restriction $44.00M.
| Period end | Equity Security Fv Ni Contractual Sale Restriction |
|---|---|
| 2024-03-31 | $123.00M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $44.00M 10-Q · filed 2024-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |